## Ciclosporin use in acute ulcerative colitis

European Journal of Gastroenterology and Hepatology 17, 79-84 DOI: 10.1097/00042737-200501000-00016

**Citation Report** 

#	Article	IF	CITATIONS
2	Review article: how and when to use ciclosporin in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2005, 22, 907-916.	1.9	48
3	Advances in therapeutic approaches to ulcerative colitis and crohn's disease. Current Gastroenterology Reports, 2005, 7, 475-484.	1.1	21
4	Management of acute severe colitis. British Medical Bulletin, 2005, 75-76, 131-144.	2.7	73
5	Medical Management of Surgical Inflammatory Bowel Disease? Current Concepts and Future Possibilities. Seminars in Colon and Rectal Surgery, 2006, 17, 50-54.	0.2	0
6	Cyclosporine: Balancing Risk and Benefit. , 0, , 55-58.		0
8	New thinking: theory vs practice. A case study illustrating evidence-based therapeutic decision making. Colorectal Disease, 2006, 8, 25-29.	0.7	4
9	Review article: saving the colon in severe colitis – the case for medical therapy. Alimentary Pharmacology and Therapeutics, 2006, 24, 68-73.	1.9	17
10	Role of infliximab in ulcerative colitis: Further questions. Inflammatory Bowel Diseases, 2006, 12, 335-337.	0.9	4
11	Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials. Inflammatory Bowel Diseases, 2006, 12, 979-994.	0.9	97
12	Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (neoral). Inflammatory Bowel Diseases, 2006, 12, 1131-1135.	0.9	32
13	Management of refractory ulcerative colitis. Current Treatment Options in Gastroenterology, 2006, 9, 234-245.	0.3	2
14	Inflammatory Bowel Disease After Liver Transplantation: Risk Factors for Recurrence and De Novo Disease. American Journal of Transplantation, 2006, 6, 1422-1429.	2.6	155
15	Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease?. Gut, 2006, 55, 6-8.	6.1	46
16	Survival in colorectal cancer: impact of body mass and exercise. Gut, 2006, 55, 8-10.	6.1	22
17	Cyclosporine for Severe Ulcerative Colitis. Annals of Pharmacotherapy, 2006, 40, 96-101.	0.9	28
18	Tacrolimusfinally!. Gut, 2006, 55, 1224-1225.	6.1	4
19	Long-Term Colectomy Rate After Intensive Intravenous Corticosteroid Therapy for Ulcerative Colitis Prior to the Immunosuppressive Treatment Era. American Journal of Gastroenterology, 2007, 102, 2513-2519.	0.2	70
20	Current management of severe ulcerative colitis. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 92-101.	1.7	51

#	Article	IF	CITATIONS
21	Cyclosporine A Inhibits the mRNA Expressions of IL-2, IL-4 and IFNGAMMA., but not TNFALPHA., in Canine Mononuclear Cells. Journal of Veterinary Medical Science, 2007, 69, 887-892.	0.3	52
22	Diagnosis and management of inflammatory bowel disease. NursePrescribing, 2007, 5, 289-296.	0.1	4
23	Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial. American Journal of Gastroenterology, 2007, 102, 601-608.	0.2	95
24	The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opinion on Drug Safety, 2007, 6, 479-485.	1.0	26
25	Predictors of early response to infliximab in patients with ulcerative colitis. Inflammatory Bowel Diseases, 2007, 13, 123-128.	0.9	166
26	Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterology, 2007, 7, 13.	0.8	83
27	Review article: steroid resistance in inflammatory bowel disease – mechanisms and therapeutic strategies. Alimentary Pharmacology and Therapeutics, 2007, 25, 111-122.	1.9	55
28	Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Alimentary Pharmacology and Therapeutics, 2007, 25, 1055-1060.	1.9	107
29	Steroid-refractory ulcerative colitis: Predictive factors of response to cyclosporine and validation in an independent cohort. Inflammatory Bowel Diseases, 2008, 14, 347-352.	0.9	48
30	Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2008, 27, 15-21.	1.9	31
31	Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2008, 28, 674-688.	1.9	84
32	Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2008, 28, 815-829.	1.9	15
33	The costâ€utility of high dose oral mesalazine for moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2008, 28, 1287-1296.	1.9	25
34	The Management of Acute Severe Colitis: ACPGBI Position Statement. Colorectal Disease, 2008, 10, 8-29.	0.7	45
35	Severe systemic cytomegalovirus infections in patients with steroid-refractory ulcerative colitis treated by an oral microemulsion form of cyclosporine: Report of two cases. Gastroenterologie Clinique Et Biologique, 2008, 32, 460-464.	0.9	9
36	Steroid-Refractory Severe Ulcerative Colitis. Drugs, 2008, 68, 1157-1167.	4.9	27
37	European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis, 2008, 2, 24-62.	0.6	473
38	Historical evolution of the management of severe ulcerative colitis. Journal of Crohn's and Colitis, 2008, 2, 263-268.	0.6	9

#	Article	IF	CITATIONS
39	Colectomy rate in acute severe ulcerative colitis in the infliximab era. Digestive and Liver Disease, 2008, 40, 821-826.	0.4	152
40	Predictive Factors of Response to Cyclosporine in Steroid-Refractory Ulcerative Colitis. American Journal of Gastroenterology, 2008, 103, 637-642.	0.2	97
41	Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. International Immunopharmacology, 2008, 8, 836-844.	1.7	169
42	Severe ulcerative colitis: present medical treatment strategies. Expert Opinion on Pharmacotherapy, 2008, 9, 447-457.	0.9	9
43	Therapeutic options in acute severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2008, 2, 357-370.	1.4	16
44	Diffuse Large B-Cell Lymphoma Complicated With Jejunal Stricture: The Palliative Role of Double-Balloon Enteroscopy. American Journal of Gastroenterology, 2008, 103, 2656-2657.	0.2	6
45	Proton Pump Inhibitors and Risk of Upper Gastrointestinal Bleeding in NSAID Users. American Journal of Gastroenterology, 2008, 103, 2658-2659.	0.2	2
46	Attachment Disorder: A Decline in the Performance of the Bravo pH System. American Journal of Gastroenterology, 2008, 103, 2663-2663.	0.2	1
47	Basiliximab and Infliximab for the Treatment of Steroid-Refractory Crohn's Disease. American Journal of Gastroenterology, 2008, 103, 2665-2665.	0.2	2
48	Acute Fatty Liver of Pregnancy with Concurrent Acute Hepatitis B Virus Infection. American Journal of Gastroenterology, 2008, 103, 2663-2665.	0.2	0
49	Endoscopic Ultrasound-Guided Fine-Needle Aspiration of a Mixed Acinar-Endocrine Carcinoma: A Case Report. American Journal of Gastroenterology, 2008, 103, 2659-2660.	0.2	15
50	The Rationale for Antibiotics in IBS. American Journal of Gastroenterology, 2008, 103, 2652-2652.	0.2	2
52	Lactulose Breath Testing and Irritable Bowel Syndrome. American Journal of Gastroenterology, 2008, 103, 2652-2653.	0.2	3
53	High Resolution Manometry: A Word of Caution. American Journal of Gastroenterology, 2008, 103, 2657-2658.	0.2	1
54	Warm Water Irrigation Is a Useful Technique During Colonoscopy. American Journal of Gastroenterology, 2008, 103, 2655-2655.	0.2	4
55	Cyclosporine in Acute Colitis. American Journal of Gastroenterology, 2008, 103, 2655-2655.	0.2	2
56	Safety and Efficacy of Cyclosporine Therapy in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2008, 103, 2654-2655.	0.2	5
57	Profound Copper Deficiency in a Patient With Gastric Bypass. American Journal of Gastroenterology, 2008, 103, 2660-2662.	0.2	25

#	Article	IF	CITATIONS
58	Adverse Events Associated With the Use of Cyclosporine in Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2008, 103, 937-943.	0.2	117
59	The Use of Infliximab for Treatment of Hospitalized Patients with Acute Severe Ulcerative Colitis. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 937-940.	1.8	41
60	Treatment of fulminant ulcerative colitis with cyclosporine A. Scandinavian Journal of Gastroenterology, 2009, 44, 1310-1314.	0.6	15
61	Treatment of Severe Ulcerative Colitis: Differences in Elderly Patients?. Digestive Diseases, 2009, 27, 315-321.	0.8	17
62	Infliximab therapy for patients with inflammatory bowel disease: 10years on. European Journal of Pharmacology, 2009, 623, S17-S25.	1.7	20
63	Treatment of choice for acute severe steroid-refractory ulcerative colitis is Remicade. Inflammatory Bowel Diseases, 2009, 15, 143-145.	0.9	10
64	Therapeutic strategies for the management of ulcerative colitis. Inflammatory Bowel Diseases, 2009, 15, 935-950.	0.9	65
65	Long-term outcome after admission for acute severe ulcerative colitis in Oxford: The 1992–1993 cohort. Inflammatory Bowel Diseases, 2009, 15, 823-828.	0.9	70
66	Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Alimentary Pharmacology and Therapeutics, 2009, 29, 308-314.	1.9	39
67	European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn's and Colitis, 2009, 3, 47-91.	0.6	757
68	Management of acute severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2009, 3, 395-405.	1.4	25
70	Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. Journal of Gastroenterology, 2010, 45, 1129-1137.	2.3	38
71	Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents. Inflammatory Bowel Diseases, 2010, 16, S1-S11.	0.9	16
72	Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Alimentary Pharmacology and Therapeutics, 2010, 31, 1036-1041.	1.9	44
73	Review article: the optimal medical management of acute severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2010, 32, 615-627.	1.9	33
74	Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3â€year followâ€up of the Swedishâ€Danish controlled infliximab study. Alimentary Pharmacology and Therapeutics, 2010, 32, 984-989.	1.9	164
75	The Asiaâ€Pacific consensus on ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 453-468.	1.4	134
76	T-cell-directed therapies in inflammatory bowel diseases. Clinical Science, 2010, 118, 707-715.	1.8	54

#	Article	IF	CITATIONS
77	Management of Acute Colitis and Toxic Megacolon. Clinics in Colon and Rectal Surgery, 2010, 23, 274-284.	0.5	32
78	Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. Journal of Crohn's and Colitis, 2010, 4, 398-404.	0.6	41
79	The pattern and outcome of acute severe colitis. Journal of Crohn's and Colitis, 2010, 4, 431-437.	0.6	276
80	Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee. American Journal of Gastroenterology, 2010, 105, 501-523.	0.2	1,080
81	Injecting drugs by a tube from appendix stump to colon may be a good method for dealing with refractory ulcerative colitis. Medical Hypotheses, 2010, 74, 631-633.	0.8	1
82	Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut, 2010, 59, 1485-1492.	6.1	71
84	Epidemiology and Natural History of Inflammatory Bowel Diseases. Gastroenterology, 2011, 140, 1785-1794.e4.	0.6	1,718
85	The use of Cyclosporin A in acute steroid-refractory ulcerative colitis: Long term outcomes. Journal of Crohn's and Colitis, 2011, 5, 91-94.	0.6	21
86	Ulcerative Colitis. New England Journal of Medicine, 2011, 365, 1713-1725.	13.9	982
87	Understanding the Use of Immunosuppressive Agents in the Clinical Management of IBD. Current Drug Targets, 2011, 12, 1364-1371.	1.0	9
88	Mucosal Healing in Ulcerative Colitis: Where do we Stand?. Current Drug Targets, 2011, 12, 1417-1423.	1.0	17
88 89	Mucosal Healing in Ulcerative Colitis: Where do we Stand?. Current Drug Targets, 2011, 12, 1417-1423. Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis. Journal of Clinical Gastroenterology, 2011, 45, 107-112.	1.0	17 66
	Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis. Journal of Clinical		
89	Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis. Journal of Clinical Gastroenterology, 2011, 45, 107-112. Does Anti-TNF Therapy Reduce the Requirement for Surgery in Ulcerative Colitis? A Systematic Review.	1.1	66
89 90	Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis. Journal of Clinical Gastroenterology, 2011, 45, 107-112. Does Anti-TNF Therapy Reduce the Requirement for Surgery in Ulcerative Colitis? A Systematic Review. Current Drug Targets, 2011, 12, 1440-1447. Topical agents for idiopathic distal colitis and proctitis. Journal of Gastroenterology and Hepatology	1.1	66 52
89 90 91	Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis. Journal of Clinical Gastroenterology, 2011, 45, 107-112. Does Anti-TNF Therapy Reduce the Requirement for Surgery in Ulcerative Colitis? A Systematic Review. Current Drug Targets, 2011, 12, 1440-1447. Topical agents for idiopathic distal colitis and proctitis. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 36-43. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. Journal of	1.1 1.0 1.4	66 52 18
89 90 91 92	Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis. Journal of Clinical Gastroenterology, 2011, 45, 107-112.         Does Anti-TNF Therapy Reduce the Requirement for Surgery in Ulcerative Colitis? A Systematic Review. Current Drug Targets, 2011, 12, 1440-1447.         Topical agents for idiopathic distal colitis and proctitis. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 36-43.         The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. Journal of Gastroenterology, 2011, 46, 129-137.	1.1       1.0       1.4       2.3	<ul> <li>66</li> <li>52</li> <li>18</li> <li>38</li> </ul>

ARTICLE IF CITATIONS # Calcineurin Inhibitors or Anti-TNF-α Agents in Severe Ulcerative Colitis: Available Options and 97 0.2 3 Limitations. Zeitschrift Fur Gastroenterologie, 2012, 50, 396-406. Predictive factors of response to intravenous ciclosporin in severe ulcerative colitis: the development of a novel prediction formula. Alimentary Pharmacology and Therapeutics, 2012, 36, 19 744-754. Strategies for the Care of Adults Hospitalized for Active Ulcerative Colitis. Clinical 99 2.4 54 Gastroenterology and Hepatology, 2012, 10, 1315-1325.e4. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis 1,106 Part 2: Current management. Journal of Crohn's and Colitis, 2012, 6, 991-1030. Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus 101 0.2 142 Statements. American Journal of Gastroenterology, 2012, 107, 179-194. Surgical treatment of ulcerative colitis in the biologic therapy era. World Journal of 1.4 Gastroenterology, 2012, 18, 1861. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era 104 0.9 54 of biologics. Inflammatory Bowel Diseases, 2012, 18, 1641-1646. Infliximab or Cyclosporine as Rescue Therapy in Hospitalized Patients with Steroid-Refractory 54 Ulcerative Colitis: A Retrospective Observational Study. Inflammatory Bowel Diseases, 2012, 18, 212-218. Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. 106 0.6 9 Réview article.. Scandinavian Journal of Gastroenterology, 2013, 48, 131-135. The GETECCU clinical guideline for the treatment of ulcerative colitis: A guideline created using 0.2 GRADE methodology. GastroenterologÃa Y HepatologÃa, 2013, 36, 483.e1-483.e46. A patient with ulcerative colitis and central serous chorioretinopathyâ€"A therapeutic dilemma. 109 0.6 6 Journal of Crohn's and Colitis, 2013, 7, e66-e68. Letter: the role of stent in the treatment of Crohn's disease strictures. Alimentary Pharmacology and Therapeutics, 2013, 37, 502-503. Letter: shortâ $\in$ term efficacy of tacrolimus in steroidâ $\in$ refractory ulcerative colitis â $\in$ " authorsâ $\in$ " reply. 111 1.9 0 Alimentary Pharmacology and Therapeutics, 2013, 37, 502-502. Ulcerative colitis: prevention of relapse. Expert Review of Gastroenterology and Hepatology, 2013, 7, 1.4 341-351. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. 113 1.9 82 infliximab. Alimentary Pharmacology and Therapeutics, 2013, 38, 294-302. PTH-097â€...Defining Patient-Centred Professionalism in Gastroenterology. Gut, 2013, 62, A250.2-A251. 114 6.1 PTH-096â€...Oral Ciclopsorin in Steroid Refractory, Acute, Severe Ulcerative Colitis. Gut, 2013, 62, 115 6.1 0 A250.1-A250. Oral Tacrolimus for the Treatment of Refractory Inflammatory Bowel Disease in the Biologic Era. Inflammatory Bowel Diseases, 2013, 19, 1490-1498.

#	Article	IF	CITATIONS
117	PTH-095â€Are IBD Patients Either CRP Producers or Non-Producers? a Longitudinal Study: Abstract PTH-095 Table 1. Gut, 2013, 62, A249.3-A250.	6.1	0
118	Management of acute severe ulcerative colitis. World Journal of Gastrointestinal Pathophysiology, 2014, 5, 579.	0.5	40
119	The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing antiâ€TNF use: a timeâ€trend study. Alimentary Pharmacology and Therapeutics, 2014, 40, 629-638.	1.9	88
120	Managing Intractable Proctitis and the Problematic Pouch. Digestive Diseases, 2014, 32, 427-437.	0.8	5
121	Practice Parameters for the Surgical Treatment of Ulcerative Colitis. Diseases of the Colon and Rectum, 2014, 57, 5-22.	0.7	148
122	Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2014, 8, 695-702.	1.4	3
123	Treatment of Distal/Left-Sided Ulcerative Colitis. , 2014, , 255-266.		0
124	The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. Journal of Crohn's and Colitis, 2014, 8, 1427-1437.	0.6	31
125	Management of acute severe ulcerative colitis (NICE CG 166). Clinical Medicine, 2015, 15, 473-476.	0.8	9
126	Surgical and medical treatment in patients with acute severe ulcerative colitis. Journal of Digestive Diseases, 2015, 16, 558-567.	0.7	21
127	A think tank of the Italian Society of Colorectal Surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: ulcerative colitis. Techniques in Coloproctology, 2015, 19, 627-638.	0.8	22
128	Management of Severe Ulcerative Colitis. Current Treatment Options in Gastroenterology, 2015, 13, 59-76.	0.3	2
129	Early investigational TNF receptor antagonists for the treatment of ulcerative colitis. Expert Opinion on Investigational Drugs, 2015, 24, 761-768.	1.9	5
130	Safety of Proctocolectomy for Ulcerative Colitis Under Elective and Non-Elective Circumstances: Preoperative Corticosteroid Treatment Worsens Outcome. Digestive Surgery, 2015, 32, 251-257.	0.6	13
131	Surgical Management of Ulcerative Colitis in the Era of Biologicals. Inflammatory Bowel Diseases, 2015, 21, 208-220.	0.9	23
132	Inflammatory Bowel Disease. Surgical Clinics of North America, 2015, 95, 1105-1122.	0.5	148
134	Managing acute severe ulcerative colitis in the hosptialised setting. Frontline Gastroenterology, 2015, 6, 241-245.	0.9	4
135	Recent trends and future directions for the medical treatment of ulcerative colitis. Clinical Journal of Gastroenterology, 2016, 9, 329-336.	0.4	29

#	Article	IF	Citations
136	Review article: the practical management of acute severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2016, 43, 482-513.	1.9	72
137	Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin. European Journal of Gastroenterology and Hepatology, 2016, 28, 369-382.	0.8	22
138	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2017, 49, 338-358.	0.4	42
139	Surgery of acute severe ulcerative colitis. Subtotal colectomy: when and how to do it?. European Surgery - Acta Chirurgica Austriaca, 2017, 49, 108-112.	0.3	2
140	Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. Revista De GastroenterologÃa De México (English Edition), 2017, 82, 46-84.	0.1	7
141	The safety of non-biological treatments in Ulcerative Colitis. Expert Opinion on Drug Safety, 2017, 16, 779-789.	1.0	29
142	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis, 2017, 11, 769-784.	0.6	876
143	DiagnÃ <sup>3</sup> stico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista De GastroenterologÃa De México, 2017, 82, 46-84.	0.4	22
144	Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989–2013): A Nationwide Multicenter Study. American Journal of Gastroenterology, 2017, 112, 1709-1718.	0.2	55
145	Cleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clinical Microbiology Reviews, 2017, 30, 191-231.	5.7	67
146	Second Korean guidelines for the management of ulcerative colitis. Intestinal Research, 2017, 15, 7.	1.0	59
148	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics, 2018, 57, 1075-1106.	1.6	21
149	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. GastroenterologÃa Y HepatologÃa (English) Tj ETQq0 0	0 ogo6T /O	ve <b>s</b> lock 10 Tf
150	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el uso de tiopurinas en la enfermedad inflamatoria intestinal. GastroenterologÃa Y HepatologÃa, 2018, 41, 205-221.	0.2	34
151	Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy. Irish Journal of Medical Science, 2018, 187, 385-392.	0.8	14
152	Acute severe ulcerative colitis: State of the art treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 32-33, 59-69.	1.0	28
153	Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World Journal of Gastroenterology, 2019, 25, 1142-1157.	1.4	55
154	Changes in the rate of and trends in colectomy for ulcerative colitis during the era of biologics and calcineurin inhibitors based on a Japanese nationwide cohort study. Surgery Today, 2019, 49, 1066-1073.	0.7	29

#	Article	IF	Citations
155	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 2019, 68, s1-s106.	6.1	1,353
156	ACG Clinical Guideline: Ulcerative Colitis in Adults. American Journal of Gastroenterology, 2019, 114, 384-413.	0.2	933
157	25 Ulcerative Colitis. , 2019, , .		0
158	Patient Selection. , 2019, , 15-29.		1
159	The Ileoanal Pouch. , 2019, , .		0
160	Optimal management of acute severe ulcerative colitis. Postgraduate Medical Journal, 2019, 95, 32-40.	0.9	15
161	Long-term outcome of patients with acute ulcerative colitis after first course of intravenous corticosteroids. Scandinavian Journal of Gastroenterology, 2021, 56, 234-238.	0.6	5
162	Calcineurin inhibitors in steroid and <scp>antiâ€TNF</scp> â€alpha refractory immune checkpoint inhibitor colitis. JCH Open, 2021, 5, 558-562.	0.7	9
163	Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clinical and Experimental Gastroenterology, 2021, Volume 14, 71-81.	1.0	14
164	Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease. Drugs and Aging, 2021, 38, 193-203.	1.3	2
165	GuÃa GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodologÃa GRADE. GastroenterologÃa Y HepatologÃa, 2020, 43, 1-57.	0.2	24
166	Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis. Ulcers, 2011, 2011, 1-7.	1.0	5
167	Use of Serum Infliximab Level Prior to Cyclosporine Salvage Therapy in Severe Ulcerative Colitis. ACG Case Reports Journal, 2014, 1, 148-150.	0.2	6
168	Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT). Health Technology Assessment, 2016, 20, 1-320.	1.3	50
169	The use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World Journal of Gastroenterology, 2008, 14, 2544.	1.4	35
170	Treatment of severe steroid refractory ulcerative colitis. World Journal of Gastroenterology, 2008, 14, 5508.	1.4	45
171	Use of mycophenolate mofetil in inflammatory bowel disease. World Journal of Gastroenterology, 2009, 15, 1594.	1.4	32
172	Current treatment of ulcerative colitis. World Journal of Gastroenterology, 2011, 17, 3204-12.	1.4	95

#	Article	IF	CITATIONS
173	Azathioprine is essential following cyclosporine for patients with steroid-refractory ulcerative colitis. World Journal of Gastroenterology, 2015, 21, 254.	1.4	19
174	First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World Journal of Gastroenterology, 2020, 26, 6710-6769.	1.4	12
175	Targeting T cells in Chronic Inflammatory Bowel Diseases. Journal of Clinical & Cellular Immunology, 2013, 04, .	1.5	4
176	Novel topical therapies for distal colitis. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2010, 1, 87.	0.6	11
177	Cytapheresis in Patients with Severe Ulcerative Colitis after Failure of Intravenous Corticosteroid: A Long-Term Retrospective Cohort Study. Gut and Liver, 2009, 3, 41-47.	1.4	3
178	Guidelines for the Management of Ulcerative Colitis. Intestinal Research, 2012, 10, 1.	1.0	12
179	The Effect of Infliximab on Patients with Ulcerative Colitis in Korea. Intestinal Research, 2014, 12, 214.	1.0	11
180	Cyclosporine in steroid refractory acute severe colitis. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 2014, 35, S21-S28.	0.0	7
183	Ulcerative Colitis: The Choice of Immunosuppressant. , 2011, , 35-41.		0
184	Conventional Medical Management of Ulcerative Colitis: Cyclosporine. , 2012, , 481-485.		0
185	Cyclosporine for Ulcerative Colitis. , 2014, , 153-166.		0
186	Safety Considerations in the Medical Therapy of Ulcerative Colitis. , 2014, , 297-311.		1
187	Infliximab for Ulcerative Colitis. , 2014, , 175-184.		0
188	Operative Therapie der Colitis ulcerosa und Pouchitis. , 2020, , 305-317.		0
189	Management of moderate to severe ulcerative colitis. , 0, , 174-180.		0
191	Indications for use of infliximab in inflammatory bowel disease. , 0, , 165-182.		0
192	Treatment of mild-to-moderate episodes of extensive ulcerative colitis. , 0, , 208-212.		0
195	Infliximab: the evidence for its place in therapy in ulcerative colitis. Core Evidence, 2008, 2, 151-61.	4.7	1

#	Article	IF	CITATIONS
196	Medical Management of Ulcerative Colitis. , 2022, , 765-779.		0
199	Conjugation of Mycophenolic Acid with Dextran: A Potential Strategy for Colon- targeted Delivery for Mitigation of Inflamed Colon in Ulcerative Colitis. Letters in Drug Design and Discovery, 2022, 19, .	0.4	0
200	Cyclosporine Therapy as a Rescue Treatment in Steroid Refractory Acute Severe Ulcerative Colitis: A Real Life Data From a Tertiary Center. , 0, , .		2
202	Long-term outcomes of patients with acute severe ulcerative colitis treated with cyclosporine rescue therapy. Scandinavian Journal of Gastroenterology, 2023, 58, 483-488.	0.6	1
203	Platelet-Rich Plasma Gel Matrix (PRP-GM): Description of a New Technique. Bioengineering, 2022, 9, 817.	1.6	2
204	Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review. Journal of Crohn's and Colitis, 2023, 17, 972-994.	0.6	10
206	Conventional treatment and new drugs. , 2023, , 47-69.		0
207	Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Przeglad Gastroenterologiczny, 2023, 18, 1-42.	0.3	1